CELLTRION, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 176,200 KRW | -0.62% |
|
-2.06% | -12.56% |
| May. 24 | Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe | CI |
| May. 10 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Neutral |
| Resistance | 194,600.00 | 231,500.00 | 214,500.00 |
| Spread/Res. | -9.46% | -23.89% | -17.86% |
| Spread/Supp. | +3.04% | +11.80% | +28.61% |
| Support | 171,000.00 | 157,600.00 | 137,000.00 |
Technical Rankings Surperformance
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Equities
- A068270 Stock
- Charts Celltrion, Inc.
